Patient Consent in Clinical Trials: Which Documents Does a Participant Sign?
Participation in a clinical trial always requires providing the patient with complete and understandable information about the project and obtaining their informed and voluntary consent. This is one of the most important aspects of conducting clinical research, as it protects the rights, safety, and well-being of participants. Patients should understand the purpose of the study, what their participation involves, which procedures will be performed, the duration of their involvement, potential benefits, risks or inconveniences, and the rights they are entitled to.
The primary document is the Informed Consent Form (ICF). It typically consists of two parts: the information section for the patient and the actual consent form. The informational section describes the study clearly and accessibly, allowing the participant to make a decision without pressure and with full understanding. The signature section confirms that the participant has read the information, had the opportunity to ask questions, received answers, and voluntarily agrees to participate in the study.
In practice, additional consent forms may also be required depending on the type of project, procedures used, nature of the data collected, and requirements of the sponsor or ethics committee. These additional consents may cover, for example, personal data processing, sharing data with entities involved in the study, use of medical records, contact with the patient under specific circumstances, or participation in procedures beyond the main study.
Special attention is given to consent related to the collection, storage, and use of biological samples. If the study involves collecting blood, tissue, or other biological material, the patient must be clearly informed about the purpose of its use, storage duration, who will have access, and whether it may be used for future analyses. Separate consent may also be required for genetic testing due to the particularly sensitive nature of the information.
Another type of consent may concern participation in a sub-study, an additional component conducted alongside the main study. Sub-studies may involve extra diagnostics, quality-of-life assessments, imaging studies, pharmacokinetic analyses, or long-term patient follow-up. Participation in such components should be voluntary and clearly described so that the patient understands whether refusal affects their involvement in the main study.
Separate rules apply to minors or patients unable to provide informed consent themselves. In these cases, a legal representative gives consent, and where possible, the participant should also receive age-appropriate information suitable for their health status and understanding. For children, an additional document confirming their agreement or assent, written in simple, age-appropriate language, is often used.
Patient consent is not merely a formality or a single signature. It is a process involving discussion with study staff, time to review materials, the opportunity to ask questions, and the right to change one’s mind. A participant may withdraw consent at any time, without providing a reason and without affecting their future medical care.
Properly prepared and explained patient consents are the foundation of ethical clinical research. They ensure transparency, build trust between the participant and the study team, and confirm that participation occurs voluntarily, knowingly, and in accordance with legal, ethical, and quality requirements.
